TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Must have received: vascular endothelial growth factor (VEGF)-targeted therapy

RCC: ...at least two prior systemic regimens, including vascular endothelial growth factor (VEGF)-targeted therapy and checkpoint inhibitor therapy

Must have received: checkpoint inhibitor therapy

RCC: ...at least two prior systemic regimens, including vascular endothelial growth factor (VEGF)-targeted therapy and checkpoint inhibitor therapy

Must have received: second-generation hormonal agent

CRPC: ...previously received a second-generation hormonal agent (unless contraindicated)

Must have received: taxane

CRPC: ...previously received ... a taxane-based chemotherapy

Must have received: platinum-based chemotherapy

SCCHN: ...progressed during or after a platinum-based chemotherapy and/or checkpoint inhibitor therapy (separately or in combination)

Must have received: checkpoint inhibitor therapy

SCCHN: ...progressed during or after a platinum-based chemotherapy and/or checkpoint inhibitor therapy (separately or in combination)

Cannot have received: anti-cancer therapy

Prior anti-cancer therapy within 4 weeks prior to the start of study intervention. A 2 week washout is acceptable for short-acting drugs (eg, tyrosine kinase inhibitors). Any treatment-related toxicities must be resolved to Grade 0 - 1.

Cannot have received: radiotherapy

Exception: A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease.

Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids and not have had radiation pneumonitis.